FY2024 EPS Estimates for Vericel Lifted by Leerink Partnrs

Vericel Co. (NASDAQ:VCEL) – Equities researchers at Leerink Partnrs upped their FY2024 earnings estimates for shares of Vericel in a research note issued to investors on Thursday, November 7th. Leerink Partnrs analyst M. Kratky now anticipates that the biotechnology company will post earnings of $0.15 per share for the year, up from their previous estimate of $0.12. The consensus estimate for Vericel’s current full-year earnings is $0.13 per share. Leerink Partnrs also issued estimates for Vericel’s Q4 2024 earnings at $0.33 EPS, Q2 2025 earnings at $0.01 EPS, Q4 2025 earnings at $0.37 EPS, FY2027 earnings at $1.35 EPS and FY2028 earnings at $1.81 EPS.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. Vericel had a net margin of 1.56% and a return on equity of 1.48%. The firm had revenue of $57.91 million for the quarter, compared to the consensus estimate of $55.32 million.

A number of other analysts also recently commented on the company. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Canaccord Genuity Group initiated coverage on shares of Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 price objective on the stock. Stephens lifted their target price on shares of Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Vericel in a research report on Friday, November 8th. Finally, Canaccord Genuity Group started coverage on Vericel in a research report on Friday, August 9th. They set a “buy” rating and a $57.00 price objective for the company. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $57.71.

Vericel Price Performance

Shares of NASDAQ:VCEL opened at $55.89 on Monday. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of 946.33 and a beta of 1.66. The business’s 50 day simple moving average is $44.37 and its 200-day simple moving average is $46.49. Vericel has a 12 month low of $32.31 and a 12 month high of $57.81.

Institutional Investors Weigh In On Vericel

Institutional investors have recently added to or reduced their stakes in the company. International Assets Investment Management LLC grew its stake in Vericel by 4,126.7% during the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after buying an additional 619 shares during the period. CWM LLC increased its holdings in Vericel by 319.0% in the 2nd quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 504 shares in the last quarter. Farther Finance Advisors LLC raised its position in Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 405 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Vericel by 22.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 322 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new stake in shares of Vericel in the third quarter worth about $92,000.

Insider Buying and Selling

In related news, Director Steven C. Gilman sold 5,833 shares of the company’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total value of $235,361.55. Following the completion of the transaction, the director now directly owns 11,000 shares in the company, valued at approximately $443,850. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Steven C. Gilman sold 5,833 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total value of $235,361.55. Following the completion of the sale, the director now directly owns 11,000 shares in the company, valued at approximately $443,850. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the transaction, the chief executive officer now directly owns 220,937 shares in the company, valued at approximately $9,142,373.06. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,166 shares of company stock worth $1,200,764. 5.20% of the stock is owned by insiders.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.